Loading…
SNTI
Senti Biosciences Holdings, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 816944102
$0.38-0.13%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $11.74M
- P/E
- —
- Forward P/E
- —
- P/B
- 4.6x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.64
- ROE
- -466.46%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.11
- 52-week high
- $2.88
- 52-week low
- $0.33
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.7% over 5Y.
today you would have $3.31▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.04 | $3.51 | $6.60 | $14.10 | $98.60 | |
| P/S | 13.8x | 1472.3x | 13.8x | 11.8x | 14.5x | 10.6x |
| P/B | 2.0x | 5.8x | 3.6x | 0.5x | 0.5x | — |
| EPS | -$2.73 | -$12.03 | -$16.01 | -$22.30 | -$190.00 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PDSBPDS Biotechnology Corp | $0.21 | — | — | — | -543.97% | $11.8M |
| KPRXKiora Pharmaceuticals Inc | $2.62 | — | 0.8x | — | -56.37% | $11.59M |
| ASBPAspire Biopharma Holdings, Inc. | $8.51 | — | 0.9x | — | -1032.14% | $11.94M |
| BLRXBioLineRx Ltd. | $2.60 |
About the company
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
- 39
- South San Francisco, United States
Company description provided by Yahoo Finance.